SBI Okasan Asset Management Co.Ltd. Purchases New Position in argenex SE $ARGX

SBI Okasan Asset Management Co.Ltd. purchased a new stake in shares of argenex SE (NASDAQ:ARGX) during the 4th quarter, according to its most recent disclosure with the SEC. The fund purchased 1,800 shares of the company’s stock, valued at approximately $1,507,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in ARGX. Capital World Investors raised its position in argenex by 0.4% in the third quarter. Capital World Investors now owns 1,959,504 shares of the company’s stock valued at $1,445,113,000 after purchasing an additional 8,422 shares during the last quarter. M&T Bank Corp raised its position in argenex by 20,977.7% in the fourth quarter. M&T Bank Corp now owns 778,610 shares of the company’s stock valued at $654,772,000 after purchasing an additional 774,916 shares during the last quarter. Wellington Management Group LLP raised its position in argenex by 80.1% in the third quarter. Wellington Management Group LLP now owns 729,986 shares of the company’s stock valued at $538,408,000 after purchasing an additional 324,653 shares during the last quarter. Bank of America Corp DE raised its position in argenex by 1.9% in the third quarter. Bank of America Corp DE now owns 342,379 shares of the company’s stock valued at $252,525,000 after purchasing an additional 6,259 shares during the last quarter. Finally, Two Sigma Investments LP raised its position in argenex by 570.3% in the third quarter. Two Sigma Investments LP now owns 294,160 shares of the company’s stock valued at $216,961,000 after purchasing an additional 250,278 shares during the last quarter. 60.32% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of research analysts recently issued reports on the stock. Guggenheim raised their price objective on shares of argenex from $1,120.00 to $1,135.00 and gave the company a “buy” rating in a report on Friday, May 8th. Royal Bank Of Canada reduced their target price on shares of argenex from $925.00 to $890.00 and set an “outperform” rating on the stock in a report on Friday, February 27th. Glj Research raised shares of argenex to a “strong-buy” rating in a report on Friday, April 3rd. Citizens Jmp boosted their target price on shares of argenex from $925.00 to $944.00 and gave the stock a “market outperform” rating in a report on Friday, February 27th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of argenex in a report on Monday, April 20th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $1,017.78.

argenex Price Performance

ARGX opened at $838.49 on Friday. The firm has a market capitalization of $52.15 billion, a price-to-earnings ratio of 37.33, a PEG ratio of 1.30 and a beta of 0.46. argenex SE has a fifty-two week low of $510.05 and a fifty-two week high of $934.62. The company’s 50 day moving average price is $776.28 and its two-hundred day moving average price is $815.12.

argenex (NASDAQ:ARGX) last issued its quarterly earnings results on Tuesday, March 31st. The company reported $5.52 earnings per share (EPS) for the quarter. The firm had revenue of $1.31 billion for the quarter. argenex had a net margin of 31.31% and a return on equity of 33.28%. As a group, equities research analysts predict that argenex SE will post 25.27 EPS for the current year.

argenex Company Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.